Solvonis Therapeutics

Timeline

Solvonis Therapeutics hits key PK milestone for esketamine AUD programme

07:35, 22 Jun 2026

Solvonis to prioritise Phase 3 for lead asset

09:39, 29 Apr 2026

Solvonis Therapeutics welcomes US executive order

09:45, 20 Apr 2026

Solvonis secures another US patent for PTSD programme

08:26, 8 Apr 2026

More in Pharma

A laboratory technician is performing an analysis in a lab setting, wearing protective gear and using pipettes. The workspace features various laboratory equipment and samples, emphasizing a research environment.

Pharma

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Positive overall survival data from a China trial of risvutatug rezetecan marks the first Phase III success for any B7-H3-targeted antibody-drug conjugate, strengthening GSK's broader development programme.

Updated 14:01, 10 Jul 2026

Biotech

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

17:02, 9 Jul 2026

Pharma

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

07:36, 9 Jul 2026

Pharma

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

13:39, 8 Jul 2026

Biotech

Physiomics wins contracts across two service lines

10:21, 8 Jul 2026

Real Estate & REITs

Segro doubles new rent secured in first half as development pipeline hits record

09:55, 8 Jul 2026

Biotech

Coiled Therapeutics advances softgel formulation ahead of dose expansion

10:42, 7 Jul 2026

Medtech & Diagnostics

MedPal AI raises £5m to acquire care-home software firm and launch oral Wegovy clinic

07:53, 3 Jul 2026

Oil & Gas

The Premarket Brief: MedPal AI raises £5m for care-home software and oral Wegovy clinic, Helix Exploration, Harbour Energy, Craneware, Ilika

07:51, 3 Jul 2026

Biotech

PureTech spins out Celea Therapeutics with $180m Raise

11:32, 2 Jul 2026

Real Estate & REITs

Supermarket Income REIT completes £445m debt refinancing at lower margin

08:34, 2 Jul 2026

Based on available information, here is the company description: Solvonis Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology and other serious diseases. The company is listed on the London Stock Exchange and operates primarily in the UK and European markets as a small-cap biotech enterprise in early-to-mid stage development. As a pre-revenue clinical-stage company, Solvonis is dependent on capital raises and partnerships to fund its pipeline advancement.

Sector: Pharma
Market: MAINMARKET

Insight

What is the primary near-term corporate value driver for Solvonis Therapeutics?

The primary near-term corporate value driver for Solvonis Therapeutics is a Phase 3 readout or value‑inflection for SVN-001 in severe AUD (UK).

Updated 22 Jun 2026

Insight

How much cash did Solvonis Therapeutics report at year-end 2025?

Solvonis Therapeutics reported year-end cash and cash equivalents of £1.720 million for the year ended 31 Dec 2025 and said this funding is expected to provide runway through the end of 2026.

Updated 22 Jun 2026

Insight

When did Solvonis Therapeutics initiate the SVN-002 Phase 2 study in the U.S.?

Solvonis Therapeutics initiated the SVN-002 Phase 2 study in the U.S. on 29 April 2026.

Updated 22 Jun 2026

Identifiers

Ticker: SVNS
Market: MAINMARKET
ISIN: GB00BMD1Z199
LEI: 2138005PH7OJRCRPUD88

Learn more on:

GLEIF Companies House

Timeline

Solvonis Therapeutics hits key PK milestone for esketamine AUD programme

Solvonis to prioritise Phase 3 for lead asset

Solvonis Therapeutics welcomes US executive order

Solvonis secures another US patent for PTSD programme

More in Pharma

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

Physiomics wins contracts across two service lines

Segro doubles new rent secured in first half as development pipeline hits record

Coiled Therapeutics advances softgel formulation ahead of dose expansion

MedPal AI raises £5m to acquire care-home software firm and launch oral Wegovy clinic

The Premarket Brief: MedPal AI raises £5m for care-home software and oral Wegovy clinic, Helix Exploration, Harbour Energy, Craneware, Ilika

PureTech spins out Celea Therapeutics with $180m Raise

Supermarket Income REIT completes £445m debt refinancing at lower margin

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer